The Claim
Oral melatonin supplementation (3–20 mg daily for 8–24 weeks) does not significantly improve left ventricular ejection fraction in patients with heart failure compared to placebo, indicating it is unlikely to enhance cardiac pumping capacity in this population.
What the research says
Challenges is higher
Challenge is ahead, but a single strong supporting study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking melatonin pills for heart failure patients doesn't seem to help their hearts pump blood better. Research shows that adding melatonin to their treatment doesn't make a meaningful difference in how well their hearts work compared to just taking a placebo.
See the scientific wording
Oral melatonin supplementation (3 to 20 mg daily for 8 to 24 weeks) does not produce a statistically significant improvement in left ventricular ejection fraction among patients with heart failure, showing a pooled mean difference of 2.39% (95% CI: -1.82 to 6.59, p=0.27) compared to placebo. This indicates that melatonin therapy is unlikely to directly enhance the heart's primary pumping capacity in this patient population.
What the research says
1 studyThe systematic review combined echocardiographic data from two randomized controlled trials assessing left ventricular ejection fraction. The pooled mean difference of 2.39% yielded a 95% confidence interval ranging from -1.82 to 6.59, and a p-value of 0.27. Because the confidence interval crosses the null value and the p-value exceeds the conventional threshold of 0.05, the evidence demonstrates a lack of statistically significant effect on this primary structural cardiac parameter.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.